Investors
MetalloBio is leading the way in developing a completely new class of antibiotics to address the rapidly emerging public health crisis associated with anti-microbial resistance. To date, the business has secured over £1m in non-dilutive seed-funding.
The Company’s current pipeline comprises two lead compounds derived from our proprietary, novel inorganic chemistry platform. Whilst the Company's R&D focus remains on the development of new drug products, our experienced management team are dedicated to the development and deployment of our technology in non-therapeutic applications via R&D partnerships and out-licensing. MetalloBio has a strong IP portfolio, with multiple pending composition of matter patent applications protecting the technology worldwide.
Invest in us.
To find out more about investment opportunities please get in touch